Clinical Trial Update: Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update indicates the addition of ipatasertib to neoadjuvant chemotherapy plus atezolizumab for triple-negative breast cancer is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• ipatasertib (ipatasertib)

Snippet

Sponsor: Queen Mary University of London | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING